FIELD: biotechnology.
SUBSTANCE: antibody is proposed which specifically binds human B7-H7CR and its antigen-binding fragment. Also contemplated are: a pharmaceutical composition, a method for treating a disease associated with B7-H7CR expression, a method for enhancing the immune response associated with the interaction of B7 and B7-H7CR, a method for the prophylactic treatment of a disease associated with B7-H7CR expression, and a method for diagnosing a disease associated with of B7-H7CR expression.
EFFECT: after present invention, the antibody enhances the immune response, and therefore may find further application in the therapy and diagnosis of various diseases.
33 cl, 23 dwg, 11 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO H7CR | 2013 |
|
RU2691428C2 |
| GENETICALLY MODIFIED, NON-HUMAN ANIMALS WITH HUMANIZED IMMUNOGLOBULIN LOCUS | 2020 |
|
RU2822367C2 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
| ANTIBODIES FOR TREATMENT OF HEPATITIS B INFECTION AND RELATED DISEASES | 2018 |
|
RU2765878C2 |
| ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1 | 2012 |
|
RU2625034C2 |
| COLLECTION AND METHODS OF ITS APPLICATION | 2010 |
|
RU2569187C2 |
| COMBINED THERAPY FOR CANCER TREATMENT | 2016 |
|
RU2731202C2 |
| COLLECTION AND METHODS FOR ITS USE | 2011 |
|
RU2603080C2 |
| HUMANISED ANTIBODY AND ANTIGENBINDING FRAGMENT (Fab), WHICH BINDS WITH HUMAN INTERFERON-γ, DNA FRAGMENTS CODING CLAIMED ANTIBODY AND ANTIGEN-BINDING FRAGMENT, CELL, TRANSFORMED BY DNA FRAGMENT, AND METHOD OF OBTAINING CLAIMED ANTIBODY AND ANTIGEN-BINDING FRAGMENT | 2013 |
|
RU2539752C2 |
| HUMANISED ANTIBODIES WITH INCREASED STABILITY | 2015 |
|
RU2684703C2 |
